一个奇怪的舞蹈夫妇. 与EGFR突变和NTRK-1转位同时存在的非小细胞肺癌:一个病例报告
Ramon Robledano1, Maria D Lozano1
1Department of Pathology, University of Navarra Clinic, Pamplona, Spain.
Diagnostic cytopathology
|April 18, 2024
概括
本案例报告详细介绍了一名非小细胞肺癌患者,其表皮生长因子受体 (EGFR) 突变和神经氨酸受体激酶1 (NTRK1) 融合,挑战了这些生物标志物相互排他性的先前假设.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 最少侵入性组织采集越来越多地用于非小细胞肺癌 (NSCLC) 的诊断和管理.
- 形态亚型和全面的生物标志物信息对于目前的NSCLC治疗是必不可少的.
- 强制性生物标志物测试包括EGFR,KRAS,BRAF,HER2,ALK的突变,以及ROS1,MET,RET和NTRK基因的融合.
研究的目的:
- 报告一个非小细胞肺癌 (NSCLC) 病例,同时出现表皮生长因子受体 (EGFR) 突变和神经氨酸受体激酶1 (NTRK1) 融合.
- 讨论在NSCLC中某些遗传变化的相互排他性的不断发展的理解.
主要方法:
- 对患者数据和分子分析结果的审查.
- 对包括EGFR突变和NTRK1融合在内的遗传变化的分析.
主要成果:
- 这名患者患有非小细胞肺癌 (NSCLC),其中包括EGFR突变和NTRK1融合.
- 这一发现挑战了以前对这些特定遗传变化的相互排他性的假设.
结论:
- 在NSCLC中,EGFR突变和NTRK1融合的同时发生是可能的.
- 全面的分子分析对于准确的NSCLC诊断和治疗计划至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
